New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients.

International Conference on Clinical Trials for Alzheimer’s Disease (CTAD) 2015, Barcelona, Spain

Steve Macfarlane, Paul Maruff, Marco Cecchi, Dennis Moore, Tasos Zografidis, Christopher Missling

View Presentation

Share this: